|By Marketwired .||
|June 2, 2014 05:35 PM EDT||
LAGUNA HILLS, CA -- (Marketwired) -- 06/02/14 -- Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl® over-the-counter homeopathic product for nausea relief.
In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its Emesyl® trademark.
The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of Emesyl® will soon begin with its manufacturer, Oasis Health Products.
The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues.
"Reaching these significant NDC and trademark milestones required a lot of hard work and patience. We have wasted no time in prompting our manufacturer to finalize all steps for the first production run of Emesyl®, bringing us one step closer to market," said Dr. Charles H. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.
The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. (http://pharma.about.com/od/Over-the-Counter-Medicine/a/The-Over-the-counter-Drug-Industry.htm)
In another development, the Company's research team received its 30 day testing feedback on its Cloud9 Project and the ITNS management team has decided to terminate the project in the interest of shareholder value. The Company, however, is moving forward with plans to expand with new innovative products and continues to seek additional ventures that will bring value to the Company and its shareholders.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
As the rapid adoption of containers continues, companies are finding that they lack the operational tools to understand the behavior of applications deployed in these containers, and how to identify issues in their application infrastructure. For example, how are multiple containers within an application impacting each other’s performance? If an application’s service is degraded, which container is to blame? In the case of an application outage, what was the root cause of the outage?
May. 4, 2016 01:45 PM EDT Reads: 1,097
May. 4, 2016 01:45 PM EDT Reads: 1,311
May. 4, 2016 01:00 PM EDT Reads: 1,411
May. 4, 2016 12:47 PM EDT Reads: 176
May. 4, 2016 12:45 PM EDT Reads: 885
May. 4, 2016 12:45 PM EDT Reads: 1,243
May. 4, 2016 12:45 PM EDT Reads: 547
May. 4, 2016 12:30 PM EDT Reads: 1,063
May. 4, 2016 12:15 PM EDT Reads: 514
May. 4, 2016 12:15 PM EDT Reads: 557
May. 4, 2016 12:15 PM EDT Reads: 1,329
May. 4, 2016 12:00 PM EDT Reads: 1,140
May. 4, 2016 12:00 PM EDT Reads: 1,162
May. 4, 2016 12:00 PM EDT Reads: 1,032
May. 4, 2016 11:15 AM EDT Reads: 1,223